Unlearn Appoints Kwame Marfo as VP of Product to Advance AI-Powered Clinical Trial Innovation
San Francisco, July 29, 2025 – Unlearn®, a company pioneering the use of AI-driven digital twins in clinical trials, has appointed Kwame Marfo as its new Vice President of Product. Marfo’s addition to the leadership team underscores Unlearn’s continued growth and focus on accelerating clinical research through predictive modeling technologies.
In this role, Marfo will lead Unlearn’s product strategy and development, ensuring that the company’s AI solutions remain aligned with the evolving needs of pharmaceutical sponsors and regulatory agencies.
“Kwame brings the rare combination of deep domain expertise and a sharp product mindset that will be invaluable as we continue to scale,” said Steve Herne, CEO of Unlearn. “His experience improving trial design and execution aligns closely with our mission to accelerate research through digital twin technology.”
A Track Record of Driving Innovation in Clinical Development
Marfo joins Unlearn from Komodo Health, where he served as Senior Director of Product Strategy and Incubation. He led cross-functional teams in developing new healthcare technology solutions for clinical development and medical affairs.
Before Komodo, Marfo spent over a decade at Genentech, holding leadership roles across global clinical operations and manufacturing sciences. As Director of Insights & Analytics for Genentech’s Global Clinical Operations, he co-founded a data-driven function focused on improving clinical trial representation, patient experience, and execution speed.
He holds a BS in Chemical Engineering from Stanford University and an MBA from the Haas School of Business at UC Berkeley.
“Unlearn is tackling one of the most longstanding challenges in healthcare by modernizing clinical trials and helping bring effective treatments to patients faster,” said Marfo. “I’m excited to join a team that’s not only leading in AI innovation, but also rethinking legacy systems with a deep commitment to scientific rigor and real-world patient impact.”
Advancing Digital Twin Adoption in Drug Development
Unlearn develops AI-powered digital twins—computational models that predict how patients in a clinical trial would progress without treatment. These forecasts can be used to enhance trial designs, reduce control arm size, and potentially accelerate timelines.
The company’s platform has gained traction across pharma and biotech, and its science-first approach has earned recognition from both FDA and EMA. As regulatory agencies show increased openness to AI-assisted methodologies, Unlearn’s work is positioned at the forefront of transforming how clinical trials are designed and run.
Unlearn Appoints Kwame Marfo as VP of Product to Advance AI-Powered Clinical Trial Innovation
San Francisco, July 29, 2025 – Unlearn®, a company pioneering the use of AI-driven digital twins in clinical trials, has appointed Kwame Marfo as its new Vice President of Product. Marfo’s addition to the leadership team underscores Unlearn’s continued growth and focus on accelerating clinical research through predictive modeling technologies.
In this role, Marfo will lead Unlearn’s product strategy and development, ensuring that the company’s AI solutions remain aligned with the evolving needs of pharmaceutical sponsors and regulatory agencies.
“Kwame brings the rare combination of deep domain expertise and a sharp product mindset that will be invaluable as we continue to scale,” said Steve Herne, CEO of Unlearn. “His experience improving trial design and execution aligns closely with our mission to accelerate research through digital twin technology.”
A Track Record of Driving Innovation in Clinical Development
Marfo joins Unlearn from Komodo Health, where he served as Senior Director of Product Strategy and Incubation. He led cross-functional teams in developing new healthcare technology solutions for clinical development and medical affairs.
Before Komodo, Marfo spent over a decade at Genentech, holding leadership roles across global clinical operations and manufacturing sciences. As Director of Insights & Analytics for Genentech’s Global Clinical Operations, he co-founded a data-driven function focused on improving clinical trial representation, patient experience, and execution speed.
He holds a BS in Chemical Engineering from Stanford University and an MBA from the Haas School of Business at UC Berkeley.
“Unlearn is tackling one of the most longstanding challenges in healthcare by modernizing clinical trials and helping bring effective treatments to patients faster,” said Marfo. “I’m excited to join a team that’s not only leading in AI innovation, but also rethinking legacy systems with a deep commitment to scientific rigor and real-world patient impact.”
Advancing Digital Twin Adoption in Drug Development
Unlearn develops AI-powered digital twins—computational models that predict how patients in a clinical trial would progress without treatment. These forecasts can be used to enhance trial designs, reduce control arm size, and potentially accelerate timelines.
The company’s platform has gained traction across pharma and biotech, and its science-first approach has earned recognition from both FDA and EMA. As regulatory agencies show increased openness to AI-assisted methodologies, Unlearn’s work is positioned at the forefront of transforming how clinical trials are designed and run.
